Return to content in this issue

 

Life-threatening idiopathic nonhistaminergic acquired angioedema with response to lanadelumab

Gamboa P, Galán C, Arrien A, Segurola A, Jáuregui I

Allergy Service, Hospital Universitario de Cruces, Barakaldo, Spain

J Investig Allergol Clin Immunol 2024; Vol. 34(1)
doi: 10.18176/jiaci.0926

Key words: Idiopathic bradykinergic angioedema, Landelumab, C1 inhibidor